["Psycho-Oncology, Volume 35, Issue 5, May 2026. ", "\nABSTRACT\n\nBackground\nTelehealth for follow‐up of survivors of colorectal cancer (CRC) represents an opportunity to reduce health resource use and provide flexibility for patients and healthcare providers (HCPs). Understanding the perspectives of HCPs who have delivered telehealth‐based CRC survivorship care is critical in determining whether this is an acceptable and appropriate model.\n\n\nAims\nTo examine the experiences of oncologists and general practitioners (GPs) who provided telehealth for CRC survivors within the Shared Care for Colorectal Cancer (SCORE) trial, focusing on implementation outcomes and perceived facilitators and barriers to implementation.\n\n\nMethods\nThis qualitative descriptive study involved semi‐structured interviews. Interviews were audio‐recorded and transcribed, and data analyzed using inductive thematic analysis.\n\n\nResults\nTwenty‐three HCPs (13 GPs, 10 oncologists) participated. Seven themes were identified: (1) forced adoption and rapid implementation of telehealth during COVID; (2) patient benefits of convenience and safety; (3) patient factors that determine appropriateness for telehealth; (4) clinical factors that preclude telehealth; (5) HCP preferences and views on quality of care; (6) technical and administrative barriers; and (7) training, technology, administrative support and reimbursement to support future telehealth use. Telehealth was considered acceptable for routine CRC follow‐up care, however required judicious use. Challenges were identified regarding technology, logistical and administrative processes, and the potential for disparities in telehealth access.\n\n\nConclusions\nThis study supports the use of telehealth for the provision of CRC survivorship care, provided that certain patient‐related and clinical characteristics are met. Future research may address decision making for telehealth use and understanding and mitigating disparities in access.\n\n\nTrial Registration\nThe Shared Care for Colorectal Cancer (SCORE) Trial is registered with the Australian New Zealand Clinical Trials Registry, ACTRN12617000004369p. Registered on 3 January 2017; protocol version 4 approved 24 February 2017\n\n"]